Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients. British journal of cancer. 2005; 93 :23–28.Lim S-T, Wong E-H, Chuah K-L, Leong S-S, Lim W-T, Tay M-H, Toh C-K, Tan E-H. Gefitinib is more effective in never-...
[4]Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L [5]同步阿帕替尼联合同步放化疗治疗Ⅲ期不可切除的非小细胞肺癌的疗效 / 知网 杨想想 [6]同步放化疗与放疗同步联合阿帕替尼治疗Ⅲ期不能手术非小细胞肺癌的临床疗效...
Gefitinib (Iressa), an orally-active tyrosine kinase inhibitor of the epidermal growth factor receptor (EGFR), is the first approved molecular-targeted drug for the management of patients with advanced non-small cell lung cancer (NSCLC). Two Phase II trials (IDEAL [Iressa Dose Evaluation in ...
To investigate this further, the INFORM study was an open-label, non-comparative phase II study of gefitinib (Iressa, ZD1839; AstraZeneca, Wilmington, DE, USA) 250mg daily in combination with 5-fluorouracil (5-FU administered as an intravenous 400mgmbolus injection followed by 2800mgminfusion ...